The return of a sign, symptom, or disease after a remission
POPULARITY
In this JCO Article Insights episode, host Michael Hughes summarizes "Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma" by Kaiser et al, published February 18, 2025, followed by an interview with JCO Associate Editor Suzanne Lentzsch. Transcript Michael Hughes: Welcome to this episode of JCO Article Insights. This is Michael Hughes, JCO's editorial fellow. Today I have the privilege and pleasure of interviewing Dr. Suzanne Lentzsch on the “Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma” by Dr. Kaiser and colleagues. At the time of this recording, our guest has disclosures that will be linked in the transcript. The urge to identify patients with aggressive disease, which is the first step in any effort to provide personalized medical care, is intuitive to physicians today. Multiple myeloma patients have experienced heterogeneous outcomes since we first started characterizing the disease. Some patients live for decades after treatment. Some, irrespective of treatment administered, exhibit rapidly relapsing disease. We term this ‘high-risk myeloma'. The Durie-Salmon Risk Stratification System, introduced in 1975, was the first formal effort to identify those patients with aggressive, high-risk myeloma. However, the introduction of novel approaches in therapeutic agents—autologous stem cell transplantation with melphalan conditioning, proteasome inhibitors like bortezomib, or immunomodulatory drugs like lenalidomide—rendered the Durie-Salmon system a less precise predictor of outcomes. The International Staging System in 2005, predicated upon the burden of disease as measured by beta-2 microglobulin and serum albumin, was the second attempt at identifying high-risk myeloma. It was eventually supplanted by the Revised International Staging System (RISS) in 2015, which incorporated novel clinical and cytogenetic markers and remains the primary way physicians think about the risk of progression or relapse in multiple myeloma. Much attention has been focused on the canonically high-risk cytogenetic abnormalities in myeloma, typically identified by fluorescence in situ hybridization: translocation t(4;14), translocation t(14;16), translocation t(14;20), and deletion of 17p. Much attention also has been focused on the fact that intermediate-risk disease, as defined by the RISS, has been shown to be a heterogeneous subgroup in terms of survival outcomes. The RISS underwent revision in 2022 to account for such heterogeneity and has become the R2-ISS, published here in the Journal of Clinical Oncology first in 2022. Translocations t(14;16) and t(14;20) were removed, and gain or amplification of 1q was added. Such revisions to core parts of a modern risk-stratification system reflect the fact that myeloma right now is in flux, both in treatment paradigms and risk-stratification systems. The field in recent years has undergone numerous remarkable changes, from the advent of anti-CD38 agents to the introduction of cellular and bispecific therapies, to the very technology we use to investigate genetic lesions. The major issue is that we're seeing numerous trials using different criteria for the definition of high-risk multiple myeloma. This is a burgeoning problem and speaks very much now to a critical need for an effort to consolidate all these criteria on at least cytogenetic lesions as we move into an era of response-adapted treatment strategies. The excellent article by Kaiser and colleagues, published in the February 2024 edition of the JCO, does just that in a far-ranging meta-analysis of data from 24 prospective therapeutic trials. All 24 trials were phase II or III randomized controlled trials for newly diagnosed and relapsed/refractory multiple myeloma. The paper takes a federated analysis approach: participants provided summaries and performed prespecified uniform analyses. The high-risk cytogenetic abnormalities examined were translocation t(4;14), gain or amplification of 1q, deletion of 17p, and translocation t(14;16), if included in the original trials. All of these were collected into zero, single, or double-hit categories, not unlike the system currently present in diffuse large B-cell lymphomas. The outcomes studied were progression-free survival and overall survival, with these analyses adhering to modified ITT principles. The authors also performed prespecified subgroup analyses in the following: transplant-eligible newly diagnosed myeloma, transplant non-ineligible newly diagnosed myeloma, and relapsed/refractory myeloma. They, in addition, described heterogeneity by the I2 statistic, which, if above 50%, denotes substantial heterogeneity by the Cochrane Review Handbook, and otherwise performed sensitivity analyses and assessed bias to confirm the robustness of their results. In terms of those results, looking at the data collected, there was an appropriate spread of anti-CD38-containing and non-containing trials. 7,724 patients were evaluable of a total 13,926 enrolled in those 24 trials: 4,106 from nine trials in transplant-eligible myeloma, 1,816 from seven trials in transplant non-ineligible myeloma, and 1,802 from eight trials in relapsed/refractory disease. ISS stage for all patients was relatively evenly spread: stage I, 34.5%; stage II, 37%; stage III, 24%. In terms of high-risk cytogenetic lesions, double-hit disease was present in 13.8% of patients, and single-hit disease was present in 37.4%. In terms of outcomes, Kaiser and colleagues found a consistent separation in survival outcomes when the cohort was stratified by the number of high-risk cytogenetic lesions present. For PFS, the hazard ratio was for double-hit 2.28, for single-hit 1.51, without significant heterogeneity. For overall survival, the hazard ratio was for double-hit disease 2.94, single-hit disease 1.69, without significant heterogeneity except in patients with double-hit disease at 56.5%. By clinical subgroups, hazard ratios remained pretty consistent with the overall cohort analysis. In transplant-eligible newly diagnosed myeloma, the hazard ratio for progression is 2.53, overall survival 4.17. For transplant non-ineligible, 1.97 progression, 2.31 mortality. Relapsed/refractory disease progression 2.05, overall mortality 2.21, without significant heterogeneity. Of trials which started recruitment since 2015, that is to say, since daratumumab was FDA approved and thus since an anti-CD38 agent was incorporated into these regimens, analysis revealed the same results, with double-hit myeloma still experiencing worse survival by far of the three categories analyzed. Risk of bias overall was low by advanced statistical analysis. In terms of subgroup analysis, double-hit results for transplant-eligible newly diagnosed myeloma may have been skewed by smaller study effects, where the upper bound of the estimated hazard ratio for mortality reached into the 15 to 20 range. In conclusion, from a massive amount of data comes a very elegant way to think about the role certain cytogenetic abnormalities play in multiple myeloma. A simple number of lesions - zero, one, or at least two - can risk-stratify. This is a powerful new prognostic biomarker candidate and, somewhat soberingly, also may confirm, or at least suggests, that anti-CD38 agents are unable to overcome the deleterious impact of certain biologic characteristics of myeloma. Where do we go from here? This certainly needs further a priori prospective validation. This did not include cellular therapies. The very scale at which this risk-stratification system operates, agnostic to specific genetic lesion, let alone point mutations, lends itself also to further exploration. And to discuss this piece further, we welcome the one and only Dr. Suzanne Lentzsch to the episode. Dr. Lentzsch serves as an associate editor for JCO and is a world-renowned leader at the bleeding edge of plasma cell dyscrasia research. Dr. Lentzsch, there are several new investigations which suggest that translocation t(4;14), for example, is itself a heterogeneous collection of patients. There are other studies which suggest that point mutations in oncogenes like TP53, which were not assessed in Kaiser et al., carry substantial detrimental impact. Is this classification system - no-hit, single-hit, double-hit - too broad a look at tumor genetics? And how do you think we will end up incorporating ever more detailed investigations into the genetics of multiple myeloma moving forward? Dr. Suzanne Lentzsch: Michael, first of all, excellent presentation of that very important trial. Great summary. And of course, it's a pleasure to be here with JCO and with you to discuss that manuscript. Let me go back a little bit to high-risk multiple myeloma. I think over the last years, we had a lot of information on what is high-risk multiple myeloma, and I just want to mention a couple of things, that we separate not only cytogenetically high-risk multiple myeloma, we also have functional high-risk multiple myeloma, with an early relapse after transplant, within 12 months, or two years after start of treatment for the non transplant patients, which is difficult to assess because you cannot decide whether this is a high-risk patient before you start treatment. You only know that in retrospective. Other forms of high-risk: extramedullary disease, circulating tumor cells/plasma cell dyscrasia, patients who never achieve MRD positivity, extramedullary multiple myeloma, or even age and frailty is a high risk for our patients. Then we have gene expression and gene sequencing. So there is so much information currently to really assess what is high-risk multiple myeloma, that is very difficult to find common ground and establish something for future clinical trials. So what Dr. Kaiser did was really to develop a very elegant system with information we should all have. He used four factors: translocation t(14;16), t(4;14), gain or amplification of 1q, and deletion of 17p. Of course, this is not the entire, I would say, information we have on high risk, but I think it's a good standard. It's a very elegant system to really classify a standard single-hit, double-hit, high-risk multiple myeloma, which can be used for all physicians who treat multiple myeloma, and especially, it might also work in resource-scarce settings. So, ultimately, I think that system is an easy-to-use baseline for our patients and provides the best information we can get, especially with a baseline, in order to compare clinical trials or to compare any data in the future. Michael Hughes: Thank you, Dr. Lentzsch. To the point that you made about this isn't the full story. There does, as you said, exist this persistent group of functional high-risk multiple myeloma where we see standard-risk cytogenetics, but these patients ultimately either exhibit primary refractory disease or very early relapse despite aggressive, standard aggressive treatment. How do you see risk-stratification systems incorporating other novel biomarkers for such patients? Is it truly all genetic? Or is next-generation sequencing, gene expression profiling, is that the answer? Or is there still a role for characterizing tumor burden? Dr. Suzanne Lentzsch: Excellent question, Michael, and I wish I would have the glass ball to answer that question. I see some problems with the current approach we have. First of all, to do the cytogenetics, you need good material. You only detect and identify what you have. If the bone marrow is of low quality, you have mainly peripheral blood in your bone marrow biopsy, you might not really fully have a representation of all cytogenetic changes in your bone marrow. So I think with a low-quality sample, that you might miss one or the other really cytogenetic high risk. So, having said this, I think circulating tumor cells, that might be something we will look into in the future, because circulating tumor cells are readily available, can be assessed without doing a bone marrow biopsy. And what is even more exciting, in addition to the circulating tumor cells or plasma cells, using them is next-generation sequencing. I think at the moment, we are more in a collection phase where we really try to correlate sequencing with our cytogenetics and especially to establish next-generation sequencing in all of our patients. But I think after that collection phase, maybe in the future, collecting peripheral blood and doing sequencing on peripheral blood samples might be the way to go. In addition, I don't want to forget the imaging. We started with a skeletal survey, and we know that you probably need to lose 30% of the bone before you see a lesion at all. So having imaging, such as diffusion-weighted imaging, whole-body MRI, is also, together with sequencing of the tumor cells, a step into the right direction. Michael Hughes: Thank you, Dr. Lentzsch. Bringing this back to the article at hand, how has Kaiser et al. changed the way we discuss myeloma with patients in the exam room? Dr. Suzanne Lentzsch: I think we have more data on hand. So far, we talked about standard risk and high risk, but I think right now, with a very simple system, we can go into the room and we can tell the patient, "Listen, you don't have any of those cytogenetic abnormalities. I think you have a standard risk. We might give you a simple maintenance treatment with Revlimid." But we might also go into the room and say, "I'm really concerned. You have so-called double-hit multiple myeloma. You have high-risk and at least two of those abnormal cytogenetics which we discussed, and I think you need a more intense maintenance treatment, for instance, double maintenance." I think we know that a high-risk multiple myeloma can be brought into a remission, but the problem that we have is to keep those patients into a remission. So, I think a more intense treatment, for instance, with a double maintenance, or with consolidation after transplant, and a longer and more intense treatment is justified in patients who have that truly high-risk multiple myeloma described here. Michael Hughes: Dr. Lentzsch, thank you so much for your time and your wisdom. Dr. Suzanne Lentzsch: My pleasure. Thank you for having me. Michael Hughes: Listeners, thank you for listening to JCO Article Insights. Please come back for more interviews and article summaries, and be sure to leave us a rating and review so others can find our show. For more podcasts and episodes from ASCO, please visit ASCO.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.
Featuring a slide presentation from Dr Matthew Matasar and related discussion from Dr Carla Casulo, Dr Matasar and Dr Laurie H Sehn, including the following topics: EZH2 Inhibitors for Follicular Lymphoma (FL) (0:00) Bruton Tyrosine Kinase Inhibitors for FL (5:43) Anti-CD19 Antibodies for FL (9:40) Other Novel Agents Under Clinical Development for FL (18:50) Case: A woman in her early 80s with multiple comorbidities and relapsed FL (23:06) Case: A man in his early 40s with high-risk progressive FL that did not achieve deep remission with prior therapy (27:07) Case: A woman in her early 70s with rheumatoid arthritis and relapsed FL (33:46) CME information and select publications
Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, Dr Matthew Matasar from Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Laurie H Sehn from BC Cancer Centre for Lymphoid Cancer in Vancouver discuss recent updates on available and novel treatment strategies for relapsed/refractory follicular lymphoma. CME information and select publications here.
Family Reconnect Waitlist: https://www.realrecoverytalk.com/frc In this episode, we sit down with Brian, who shares his powerful journey through nearly four years of sobriety. Brian opens up about the brutal depths his addiction took him, and what it finally took for him to get clean. But his story takes a turn — even after spending a full year in treatment, he relapsed almost immediately upon leaving. Why? That's what we dig into. Brian reflects on his lack of willingness during that time and the truth he wasn't ready to face. Joining us is Nicole, who was Brian's therapist during his original treatment stay back in 2017. She offers insight into what might have been missing, the patterns she saw, and why sometimes relapse is part of the journey — not the end of it. This is a real, honest look at what recovery really takes, and why simply being in treatment isn't enough if you're not willing to do the inner work. Treatment Prep Guide: https://www.realrecoverytalk.com/treatmentprep SoberLink: https://www.soberlink.com/partners-family-and-friends/rrt Join our Big Book Study! https://www.realrecoverytalk.com/bigbookstudy Join our FREE FB Support group!: https://www.facebook.com/groups/realrecoverytalk Download our free guides!: https://www.realrecoverytalk.com/guides Tom IG: https://www.instagram.com/realrecoverytalktom/ Ben IG: https://www.instagram.com/realrecoverytalkben/ RRT IG: https://www.instagram.com/realrecoverytalkpodcast/
Featuring a slide presentation from Dr Matthew Matasar and related discussion from Dr Carla Casulo, Dr Matasar and Dr Laurie H Sehn, including the following topics: Overview of Chimeric Antigen Receptor (CAR) T-Cell Therapies for Relapsed/Refractory Follicular Lymphoma (FL) (0:00) Case: A man in his late 60s with relapsed FL who received axicabtagene ciloleucel (axi-cel) but experienced cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome and chronic cytopenia (3:50) Published Clinical Data Involving Axi-cel (10:24) Case: A man in his mid 60s with multiple comorbidities and progressive FL who received tisagenlecleucel (tis-cel) (15:34) Published Clinical Data Involving Tis-cel (19:47) Case: A woman in her late 40s with multiple comorbidities and refractory FL who received lisocabtagene maraleucel (liso-cel) after prior mosunetuzumab (22:43) Published Clinical Data Involving Liso-cel (26:05) Incidence and Management of Toxicities Associated with CAR T-Cell Therapy (27:48) Sequencing Considerations and Ongoing Trials Involving CAR T-Cell Therapy (30:35) Practical Considerations and Referrals for CAR T-Cell Therapy Administration (31:59) CME information and select publications
Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, Dr Matthew Matasar from Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Laurie H Sehn from BC Cancer Centre for Lymphoid Cancer in Vancouver discuss recent updates on available and novel treatment strategies for relapsed/refractory follicular lymphoma. CME information and select publications here.
This episode features leading experts Paolo Ghia, MD, Vita-Salute San Raffaele University, Milan, Italy, and Arnon Kater, MD, PhD, University... The post Updates to the ESMO CLL clinical practice guidelines and implications for relapsed therapy appeared first on VJHemOnc.
Featuring a slide presentation from Dr Matthew Matasar and related discussion from Dr Carla Casulo, Dr Matasar and Dr Laurie H Sehn, including the following topics: Overview of Bispecific Antibodies for the Treatment of Relapsed/Refractory (R/R) Follicular Lymphoma (FL) (0:00) Clinical Data Available with Mosunetuzumab for R/R FL (1:54) Clinical Data Available with Epcoritamab for R/R FL (4:54) Clinical Data Available with Odronextamab for R/R FL (6:53) Clinical Considerations in Selecting Among Available Bispecific Antibodies for R/R FL (8:34) Practical Considerations in the Administration of Bispecific Antibodies (15:21) The Role of Vaccinations in the Prevention of Infections for Patients Receiving Bispecific Antibodies (18:34) Ongoing Clinical Trials Evaluating Bispecific Antibodies for FL (21:34) Case: A man in his late 60s with refractory FL who received mosunetuzumab monotherapy (24:24) Case: A woman in her late 50s with relapsed FL who received third-line epcoritamab monotherapy (30:14) Case: A man in his late 80s with a long-standing history of FL who received odronextamab in combination with a second novel bispecific antibody (33:48) CME information and select publications
Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, Dr Matthew Matasar from Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Laurie H Sehn from BC Cancer Centre for Lymphoid Cancer in Vancouver discuss recent updates on available and novel treatment strategies for relapsed/refractory follicular lymphoma. CME information and select publications here.
In this week's episode we'll learn about the role of autologous transplant for relapsed myeloma. In an updated analysis of the GMMG ReLApsE trial, salvage autologous transplant offered no survival benefit compared to control chemotherapy. These findings may have clinical implications in an era of alternative, and highly effective, treatment options. After that: Response to DDAVP, or desmopressin, in bleeding disorders. This study is the first large scale meta-analysis to assess the response rate to DDAVP in bleeding disorders. Authors provide new insights into determinants of response, which vary according to the disease type. Finally, turning to diffuse large B cell lymphoma. Germinal center B cells depend on the activity of DOT1 and EZH2 to maintain their pro-proliferative identity. New research shows that combined treatment with DOT1L and EZH2 inhibitors has synergistic activity in vitro.Featured Articles:Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trialDDAVP response and its determinants in bleeding disorders: a systematic review and meta-analysisTargeting DOT1L and EZH2 synergizes in breaking the germinal center identity of diffuse large B-cell lymphoma
CME credits: 0.25 Valid until: 15-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/chairperson-perspective-core-concepts-for-community-based-practice-the-evolving-role-of-bispecific-antibody-therapy-in-relapsed-or-refractory-follicular-lymphoma/29191/ Dr. Tycel Phillips presents a summary and offers expert insights on relevant and timely advances in bispecific antibody therapy for the treatment of R/R FL. The activity reviews topics including differentiating approved bispecific antibodies, evidence- and guideline-based treatment planning, patient selection, practical considerations, and optimizing safety in the application of bispecific antibody therapy in R/R FL.=
In this week's episode we'll learn about the role of interleukin-1 signaling in the bone marrow microenvironment in the development of myelodysplastic syndromes, the immune checkpoint regulator VISTA as a potential target for preventing graft-vs-host disease, and epcoritamab plus gemcitabine and oxaliplatin in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma.Featured Articles:IL-1R1 and IL-18 signals regulate mesenchymal stromal cells in an aged murine model of myelodysplastic syndromesTargeting cell-surface VISTA expression on allospecific naïve T cells promotes toleranceEpcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial
The fight against relapsed/refractory multiple myeloma is evolving rapidly, with groundbreaking research and clinical trials paving the way for innovative treatments. But as new therapies emerge, addressing healthcare disparities and improving access to these life-changing advancements has never been more critical. In this episode, Dr. Rahul Banerjee, Assistant Professor of Medicine at Fred Hutchinson Cancer Center and co-chair of i3 Health's Multiple Myeloma Task Force activity, shares his expert perspective on the latest developments in CAR T-cell therapy and bispecific antibodies. He also highlights ongoing efforts to make these cutting-edge treatments more practical and accessible for patients, ensuring no one is left behind in the fight against this challenging disease. Don't miss this engaging discussion packed with actionable insights for healthcare professionals. After listening, take the next step by exploring the full Task Force activity and related resources to deepen your understanding and make a difference in your practice. Click below to access these valuable resources: Accredited CME/NCPD Podcast: bit.ly/3B4gSB1 Position Statement in Blood Cancer Journal: www.nature.com/articles/s41408-024-01129-0 Live Task Force Recording: www.youtube.com/live/TILCPB6w3Ig?…=1Z8m4dA2qwLJd6rN
Addiction Unlimited Podcast | Alcoholism | Life Coach | Living Sober | 12 Steps
If you've relapsed recently or had a drink after a solid streak of sobriety, I want you to take a deep breath and hear this: ✨ You are not broken.✨ You have not failed.✨ And you are absolutely not alone. Whether it's a one-time slip or a full-on spiral, relapse doesn't mean you've failed. It's feedback. And it's fixable. If you're feeling stuck in guilt, shame, or that voice in your head telling you, “You blew it,” this episode is your safe space to breathe, regroup, and move forward.
I Relapsed for a Woman: Lust, Cocaine, and the Lie of ControlA raw confession: what led to the slip, what it revealed about ego, love, and addiction — and how you claw your way back with style and power.→ The allure of chaos. The myth of control. The addict's ego dressed in desire.If you're done with fluff and ready to hear something real — you're in the right place.
- Review of Chronic Lymphocytic Leukemia - Significant Role of Testing in Informing Your Treatment Choices - First-Line Treatment Options - Treatment of Relapsed & Refractory CLL - Re-Testing Importance in Determining Treatment for 2nd & 3rd Line Treatments - Current Perspectives on New & Emerging Treatments of CLL - Updates on Clinical Trials & Their Significance for CLL - Key Questions to Ask & Re-Ask Your Health Care Team - Practical and Psychosocial Support to Cope with CLL - Questions for Our Panel of Expert
Chronic Lymphocytic Leukemia CancerCare Connect Education Workshops
- Review of Chronic Lymphocytic Leukemia - Significant Role of Testing in Informing Your Treatment Choices - First-Line Treatment Options - Treatment of Relapsed & Refractory CLL - Re-Testing Importance in Determining Treatment for 2nd & 3rd Line Treatments - Current Perspectives on New & Emerging Treatments of CLL - Updates on Clinical Trials & Their Significance for CLL - Key Questions to Ask & Re-Ask Your Health Care Team - Practical and Psychosocial Support to Cope with CLL - Questions for Our Panel of Expert
- Review of Chronic Lymphocytic Leukemia - Significant Role of Testing in Informing Your Treatment Choices - First-Line Treatment Options - Treatment of Relapsed & Refractory CLL - Re-Testing Importance in Determining Treatment for 2nd & 3rd Line Treatments - Current Perspectives on New & Emerging Treatments of CLL - Updates on Clinical Trials & Their Significance for CLL - Key Questions to Ask & Re-Ask Your Health Care Team - Practical and Psychosocial Support to Cope with CLL - Questions for Our Panel of Expert
In today's episode, we'll discuss time-limited triplet therapy in relapsed or refractory CLL. Zanubrutinib, venetoclax and obinutuzumab induced deep remissions, and was well tolerated, even in very high-risk patients, and those with prior exposure to targeted therapies. After that: researchers chronicle the development of a patient-reported outcome measure for sclerosis associated with chronic GVHD—graft-versus-host disease. The new symptom scale—currently undergoing validation studies—may provide valuable information regarding severity, functional impact, and response to therapy. Finally, a study of changes in population dynamic rates that underlie inflammation-associated myeloid bias. The work demonstrates the use of mathematical models to deliver critical biological insights and uncover underlying mechanisms.Featured Articles:MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trialDevelopment of the Lee Symptom Scale–Skin Sclerosis for chronic GVHD–associated sclerosisPopulation dynamics modeling reveals that myeloid bias involves both HSC differentiation and progenitor proliferation biases
Prof Martin Hutchings from Copenhagen University Hospital in Denmark, Dr Manali Kamdar from the University of Colorado Cancer Center, Dr Matthew Lunning from the University of Nebraska Medical Center and Prof Gilles Salles from Memorial Sloan Kettering Cancer Center in New York summarize currently available data guiding treatment decision-making for patients with relapsed/refractory diffuse large B-cell lymphoma and present cases from their practices.CME information and select publications here.
Featuring slide presentations and related discussion from Prof Martin Hutchings, Dr Manali Kamdar, Dr Matthew Lunning and Prof Gilles Salles, including the following topics: Evolving Role of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Kamdar (0:00) Case: A 61-year-old man with Stage IV non-GCB DLBCL receives R-CHOP but experiences disease progression 8 months later (30:39) Case: A 68-year-old man with double-hit DLBCL who experiences disease progression on chemotherapy and second-line CAR T-cell therapy receives glofitamab (39:22) Incorporation of Bispecific Antibody Therapy into DLBCL Management — Prof Hutchings (45:25) Case: A 42-year-old man with progressive DLBCL refractory to 2 lines of therapy receives glofitamab with a durable response (1:07:30) Case: An 81-year-old woman with multiregimen-refractory DLBCL experiences a prolonged response to epcoritamab (1:14:25) Case: A 69-year-old man with follicular lymphoma transformed to DLBCL and refractory to 3 lines of treatment receives glofitamab (1:21:48) Selection and Sequencing of Other Available Therapies for Relapsed/Refractory (R/R) DLBCL — Prof Salles (1:24:37) Case: An 82-year-old woman with follicular lymphoma transformed to DLBCL receives tafasitamab/lenalidomide (1:42:05) Case: A 69-year-old man with urinary bladder carcinoma and recurrent GCB DLBCL receives loncastuximab tesirine (1:46:26) Promising Investigational Approaches for Patients with R/R DLBCL — Dr Lunning (2:00:37) Case: An 80-year-old woman with multiregimen-refractory GCB DLBCL seeks treatment requiring minimal clinic visits and receives loncastuximab tesirine (2:15:59) Case: A 54-year-old man with primary refractory non-GCB DLBCL receives CAR T-cell therapy, and follow-up imaging on day 29 demonstrates a Deauville score of 4 (2:25:22) CME information and select publications
Prof Martin Hutchings from Copenhagen University Hospital in Denmark, Dr Manali Kamdar from the University of Colorado Cancer Center, Dr Matthew Lunning from the University of Nebraska Medical Center and Prof Gilles Salles from Memorial Sloan Kettering Cancer Center in New York summarize currently available data guiding treatment decision-making for patients with relapsed/refractory diffuse large B-cell lymphoma and present cases from their practices.CME information and select publications here.
In this week's episode we'll find out about longer term results from a pivotal trial of mosunetuzumab in relapsed/refractory follicular lymphoma, potential use of CD70 CAR T-cells that secrete an anti-CD33/anti-CD3 bispecific antibody as a therapy for acute myeloid leukemia, and how ferroptosis regulates hemolysis in stored red blood cells.Featured Articles:Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapiesCD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AMLFerroptosis regulates hemolysis in stored murine and human red blood cells
This week, we talk all about disseminated testicular cancer, highlighting our current treatment modalities and why we do what we do. We also cover refractory disease. This episode builds on our prior discussions in Parts 1 and 2, so be sure to check these out if you haven't already!Episode contents:- A history lesson about how we developed our current risk stratification model - Our current treatment paradigms and regimens for disseminated seminoma and non-seminoma - To resect or not to resect? - How we approach relapsed/refractory disease ****Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast
In this episode, Shaji K. Kumar, MD, reviews key data on bispecific antibodies used to treat patients with relapsed/refractory multiple myeloma recently presented at the 2024 annual American Society of Hematology meeting, including:Early results with teclistamab combined with anti-CD38 therapyReal-world data with teclistamab including its use after other BCMA-targeted therapiesTalquetamab as bridging therapy to BCMA-targeted CAR T-cell therapyEvaluation of prophylactic tocilizumab for cytokine-release syndrome associated with bispecific antibody therapyPresenter:Shaji K. Kumar, MDMark and Judy Mullins Professor of Hematologic MalignanciesConsultant, Division of HematologyProfessor of MedicineChair, Myeloma, Amyloidosis and Dysproteinemia GroupResearch Chair, Division of HematologyAssociate Chair for Research, Department of MedicineMayo ClinicRochester, MinnesotaLink to full program:https://bit.ly/40bjFCZ
Why Most Addiction Treatments Fail (And How to Fix It!) Many people enter treatment believing that the methods alone will save them, but the truth is the most important factor is often overlooked. In this episode, we dive deep into why most addiction treatments fall short—hint it's not because they lack effectiveness. We'll uncover the key ingredient that makes all the difference: motivation. Learn how shifting the focus to motivation first can create a foundation for lasting recovery and meaningful skill development. Tune in now for game-changing insights that could transform your understanding of addiction treatment and help you better support yourself or a loved one on the recovery journey. Don't miss this chance to shift your perspective on what truly drives successful change!
In this week's episode we'll learn more about a phase 2 trial of first-line zanubrutinib, obinutuzumab, and venetoclax in TP53-mutated mantle cell lymphoma; early development of hyperdiploidy in multiple myeloma; and a phase 1 trial of the asparaginase pegcrisantaspase plus venetoclax in relapsed/refractory acute myeloid leukemia.Featured Articles:Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutationDevelopment of hyperdiploidy starts at an early age and takes a decade to completeA phase 1 study of the amino acid modulator pegcrisantaspase and venetoclax for relapsed or refractory acute myeloid leukemia
After Jola Tapper's son Peter was diagnosed when he was 5 years old with Stage 4 Neuroblastoma in October of 2011, he went through a difficult treatment protocol which took him to having No Evidence of Disease on April 12th of 2012. For the next 7 1/2 years, even though he had difficulties, Peter was able to lead as normal and good of a life as possible. Then came December of 2019 and he relapsed by being diagnosed with Synovial Sarcoma. Peter was able to survive for the next 25 months, until his ultimate passing on January 17th of 2022, just 25 days before his 16th birthday.
This week, we round out our AML series with a detailed discussion about the approach to management of relapsed and refractory disease. This has been a VERY long road going through all management of AML. We hope that you have continued to build on our discussions week-to-week. An exciting treatment paradigm that is ever-evolving! Episode contents: - How do we define primary induction failure in AML? - What are options for treatment of refractory disease? What is the mechanism of action of these treatment options? - What are options for relapsed disease? - What targeted therapies are available for relapsed AML? ****This episode is sponsored by our global research partners! Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast
Please visit answersincme.com/GPV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses bispecific antibodies in the current treatment landscape of relapsed/refractory multiple myeloma. Upon completion of this activity, participants should be better able to: Review the role of bispecific antibodies in the current treatment landscape of relapsed/refractory (R/R) multiple myeloma (MM); Discuss the clinical profiles of approved and late-stage emerging bispecific antibodies in heavily pretreated R/R MM; and Describe strategies to optimize outcomes with bispecific antibodies for the treatment of R/R MM. This activity is intended for US healthcare professionals only.
Dr Alexander Perl from Abramson Cancer Center in Philadelphia, Pennsylvania, Dr Richard M Stone from Dana-Farber Cancer Institute in Boston, Massachusetts, Dr Eunice S Wang from Roswell Park Comprehensive Cancer Center in Buffalo, New York, Prof Andrew H Wei from Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, and moderator Dr Eytan M Stein from Memorial Sloan Kettering Cancer Center in New York, New York, discuss updated data from ASH 2024 influencing the current and future treatment paradigm for treatment-naïve and relapsed/refractory acute myeloid leukemia. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/ASHAML24).
Dirk Arnold, MD, PhD - Still in the Game! Optimising Treatment Sequencing in the Management of Relapsed or Refractory mCRC
Dirk Arnold, MD, PhD - Still in the Game! Optimising Treatment Sequencing in the Management of Relapsed or Refractory mCRC
Dirk Arnold, MD, PhD - Still in the Game! Optimising Treatment Sequencing in the Management of Relapsed or Refractory mCRC
In this week's episode, we'll be comparing BTK inhibitors in relapsed/refractory CLL. Then, we'll hear how researchers in the UK unraveled the genetic background of the AnWj blood group. Finally we'll learn about the role of BCL-2 and BAFF in CLL cell survival following venetoclax therapy. Featured Articles:Deletions in the MAL gene result in loss of Mal protein, defining the rare inherited AnWj-negative blood group phenotypeSustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINEVenetoclax dose escalation rapidly activates a BAFF/BCL-2 survival axis in chronic lymphocytic leukemia
Discover key updates on emerging immunotherapy combinations in relapsed/refractory (R/R) follicular lymphoma (FL) from the hematology congress in San Diego. Credit available for this activity expires: 12/18/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002061?ecd=bdc_podcast_libsyn_mscpedu
In this week's episode we'll learn more about how clonal hematopoiesis affects prognosis in patients with telomere biology disorders, consider recently uncovered molecular subtypes of extracutaneous juvenile xanthogranulomas, and discuss a clinical trial of the BCMA-CD3 bispecific antibody teclistamab in patients with relapsed/refractory multiple myeloma who have received previous BCMA-targeted therapy.Featured Articles:Clonal landscape and clinical outcomes of telomere biology disorders: somatic rescue and cancer mutationsRecurrent CLTC::SYK fusions and CSF1R mutations in juvenile xanthogranuloma of soft tissueEfficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies
Been a month since it happened. --- Support this podcast: https://podcasters.spotify.com/pod/show/the2020podcastllc/support
In this week's episode we'll learn more about a new risk classification scheme for use in patients with acute myeloid leukemia who are ineligible for intensive therapy, efficacy and safety of daratumumab plus chemotherapy in pediatric patients with acute lymphoblastic leukemia or lymphoblastic lymphoma, and a blood bank-compatible method for creating genetically engineered platelets with a wide range of potential uses.Featured Articles:Genetic Risk Stratification and Outcomes Among Treatment-Naive Patients with AML Treated With Venetoclax and Azacitidine Daratumumab in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: DELPHINUS Study Genetic Engineering of Transfusable Platelets with mRNA-Lipid Nanoparticles is Compatible with Blood Banking Practices
Carley Rutledge went through much of 2010 in pain but not getting any correct answers about the cause of this pain for most of that year, until she received the shocking diagnosis of Ewings Sarcoma. Carley went through 2 years of difficult treatment and then was given an immunotherapy drug that worked and she experienced 8 years of being cancer free from this form of Pediatric Bone Cancer. Always active and with many accomplishments, Carley then felt back pain during her run in a Half Marathon which unfortunately indicated her Ewings Sarcoma had relapsed, and this led to her passing in November of 2021 at the age of 27. Carley's mother Laura will talk about her beloved daughter and about her family's Rutledge Cancer Foundation on today's podcast.
On this episode we sit down with Jordan and discuss growing up in Georgia, dating older women, being raised by grandparents, candles, rehab, third degree burns and finding running. Follow Jordan: @jlawson0 on IGPod Socials!Instagram @twopacktaperFollow the hosts!Tik Tok @mak_n_chz & @paulkennethallenInstagram @runwithmak & @paulkennethallenYoutube @paulkennethallenSubscribe, listen, and enjoy wherever you find your podcasts! Support this podcast at — https://redcircle.com/two-pack-taper/donations
In today's episode, supported by Citius Pharmaceuticals, we had the pleasure of speaking with Francine Foss, MD, to discuss the FDA approval of denileukin diftitox-cxdl (Lymphir) for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma (CTCL) who have received 1 or more prior systemic therapies. Dr Foss is a professor of medicine (hematology) and dermatology and the director of the Multidisciplinary T Cell Lymphoma Program at the Yale School of Medicine, as well as the scientific leader of Lymphoma CRT at Yale Cancer Center in New Haven, Connecticut. On August 8, 2024, the FDA approved denileukin diftitox for the treatment of patients with relapsed/refractory CTCL who have received at least 1 prior systemic therapy. This regulatory decision was supported by findings from the phase 3 Study 302 (NCT01871727), in which patients who received the agent (n = 69) achieved an objective response rate of 36.2% (95% CI, 25.0%-48.7%) per independent review committee assessment, including a complete response rate of 8.7%. In our exclusive interview, Dr Foss discussed the significance of this approval, key efficacy and safety data from Study 302, and her excitement about reintroducing an agent to the CTCL treatment paradigm that can induce particularly robust responses.
After 2 year old Max Gagnon was diagnosed with B Cell Acute Lymphoblastic Leukemia in 2014 and went into remission , the hope and expectation for his dad Michael and mother Amber was that the worst was behind them. Max however, relapsed in 2022 and just completed his treatment in August of this year. Michael will talk about the past 10 years which hopefully will now lead to a path of good health for Max.
Staying abreast of recent clinical practice guidelines for the management of relapsed/refractory mantle cell lymphoma can be challenging for providers who may seldom encounter it in community practice. In this episode, CANCER BUZZ speaks with Jeff Sharman, MD, medical director of hematology research, US Oncology, and director of research, Willamette Valley Cancer Institute, about the role of biomarker testing in guiding treatment decisions and how evidence-based management of treatment-related adverse events can serve this patient population. “Fortunately, treatments such as BTK inhibitors are generally very well tolerated by patients, and there are very few patients who can't take a BTK inhibitor. But as you go up the scale of increasing intensity, such as CAR T-cell, or even allogeneic stem cell transplantation, those are therapies not suitable for patients with more extensive comorbidities.” – Dr. Jeff Sharman, MD “A collaborative relationship between a community practice and an academic center can be of considerable benefit to a patient, so that as treatment decisions are made, both the physician and patient can feel like they're offering the patient the very best therapy.” – Dr. Jeff Sharman, MD Jeff Sharman, MD Medical Director of Hematology Research, US Oncology Director of Research Willamette Valley Cancer Institute Eugene, Oregon This project is made possible by funding and support provided by Eli Lilly and in collaboration with The Leukemia & Lymphoma Society. Resources Treatment for Relapsed/Refractory Mantle Cell Lymphoma Tip Sheet - ACCC Relapsed/Refractory Mantle Cell Lymphoma Educational Video Series: Update on New Therapies: https://vimeo.com/942756449 BTK Inhibitors in MCL: https://vimeo.com/942755401 R/R MCL Case Studies: https://vimeo.com/942754652 BTK Inhibitors Stretch Frontline Approaches in Mantle Cell Lymphoma – Targeted Oncology Emerging Data Continue to Affect BTK Inhibitor Usage in Mantle Cell Lymphoma - OncLive HCP Fact Sheet: Facts About CAR T-cell Therapy The CAR T-cell Therapy Process Patient-Caregiver CAR T-cell Therapy Facts Learn About CAR T-cell Therapy Mantle Cell Lymphoma Facts for Patients and Caregivers -The Leukemia & Lymphoma Society
The range of frontline therapy options for mantle cell lymphoma can influence subsequent treatment choices for patients with relapsed or refractory disease. Providers must determine initial treatment based on individual patient characteristics, while also factoring in future treatment options. In this episode, CANCER BUZZ speaks with Nirav Shah, MD, MSHP, associate professor of medicine at Medical College of Wisconsin and Kirollos Hanna, PharmD, BCOP, PCOP, FACCC, assistant professor of pharmacy at Mayo Clinic and director of pharmacy at Minnesota Oncology, about shared decision making in the management of relapsed or refractory mantle cell lymphoma. “The key to all of this is good collaboration between the community and their affiliates… their partners and academics, or tertiary referral centers, to really engage… these patients in a collaborative format… it really takes a team, a village, to take care of complex mantle cell lymphoma patients. “ –Dr. Nirav Shah, MD, MSHP “We're not really seeing a lot of CAR T-cell therapy move in the frontline setting just yet, while there are a lot of ongoing clinical trials… Really, right now, it's going to be the patient characteristic: how well they did on frontline therapy, access to care, affordability, institutional preparedness… that would potentially… allow your patient to receive CAR T-cell therapy.” –Kirollos Hanna, PharmD, BCPS, PCOP, FACCC Nirav Shah, MD, MSHP Associate Professor of Medicine Medical College of Wisconsin Division of Hematology and Oncology Milwaukee, Wisconsin Kirollos Hanna, PharmD, BCPS, PCOP, FACCC Assistant Professor of Pharmacy, Mayo Clinic Director of Pharmacy Minnesota Oncology St. Paul, Minnesota This project is made possible by funding and support provided by Eli Lilly and in collaboration with The Leukemia & Lymphoma Society. Resources Treatment for Relapsed/Refractory Mantle Cell Lymphoma Tip Sheet - ACCC Relapsed/Refractory Mantle Cell Lymphoma Educational Video Series: Update on New Therapies: https://vimeo.com/942756449 BTK Inhibitors in MCL: https://vimeo.com/942755401 R/R MCL Case Studies: https://vimeo.com/942754652 BTK Inhibitors Stretch Frontline Approaches in Mantle Cell Lymphoma – Targeted Oncology Emerging Data Continue to Affect BTK Inhibitor Usage in Mantle Cell Lymphoma - OncLive HCP Fact Sheet: Facts About CAR T-cell Therapy - https://www.lls.org/sites/default/files/2023-10/FSHP1_CART_Factsheet_June2022_rev.pdf The CAR T-cell Therapy Process - https://www.lls.org/sites/default/files/2024-03/PS100_CART-CellTherapyProcessFlyer_0224.pdf Patient-Caregiver CAR T-cell Therapy Facts - https://www.lls.org/sites/default/files/2024-04/FS27_CART_Fact_Sheet_0424_rev.pdf Learn About CAR T-cell Therapy - https://www.lls.org/sites/default/files/2024-03/PS126_CART_ResourceCard_3_24.pdf Mantle Cell Lymphoma Facts for Patients and Caregivers -The Leukemia & Lymphoma Society https://lls.org/sites/default/files/2023-08/FS4_Mantle_Cell_Facts_0423rev.pdf
The range of frontline therapy options for mantle cell lymphoma can influence subsequent treatment choices for patients with relapsed or refractory disease. Providers must determine initial treatment based on individual patient characteristics, while also factoring in future treatment options. In this episode, CANCER BUZZ speaks with Nirav Shah, MD, MSHP, associate professor of medicine at Medical College of Wisconsin and Kirollos Hanna, PharmD, BCOP, PCOP, FACCC, assistant professor of pharmacy at Mayo Clinic and director of pharmacy at Minnesota Oncology, about shared decision making in the management of relapsed or refractory mantle cell lymphoma. “The key to all of this is good collaboration between the community and their affiliates… their partners and academics, or tertiary referral centers, to really engage… these patients in a collaborative format… it really takes a team, a village, to take care of complex mantle cell lymphoma patients. “ –Dr. Nirav Shah, MD, MSHP “We're not really seeing a lot of CAR T-cell therapy move in the frontline setting just yet, while there are a lot of ongoing clinical trials… Really, right now, it's going to be the patient characteristic: how well they did on frontline therapy, access to care, affordability, institutional preparedness… that would potentially… allow your patient to receive CAR T-cell therapy.” –Kirollos Hanna, PharmD, BCPS, PCOP, FACCC Nirav Shah, MD, MSHP Associate Professor of Medicine Medical College of Wisconsin Division of Hematology and Oncology Milwaukee, Wisconsin Kirollos Hanna, PharmD, BCPS, PCOP, FACCC Assistant Professor of Pharmacy, Mayo Clinic Director of Pharmacy Minnesota Oncology St. Paul, Minnesota This project is made possible by funding and support provided by Eli Lilly and in collaboration with The Leukemia & Lymphoma Society. Resources Treatment for Relapsed/Refractory Mantle Cell Lymphoma Tip Sheet - ACCC Relapsed/Refractory Mantle Cell Lymphoma Educational Video Series: Update on New Therapies: https://vimeo.com/942756449 BTK Inhibitors in MCL: https://vimeo.com/942755401 R/R MCL Case Studies: https://vimeo.com/942754652 BTK Inhibitors Stretch Frontline Approaches in Mantle Cell Lymphoma – Targeted Oncology Emerging Data Continue to Affect BTK Inhibitor Usage in Mantle Cell Lymphoma - OncLive HCP Fact Sheet: Facts About CAR T-cell Therapy - https://www.lls.org/sites/default/files/2023-10/FSHP1_CART_Factsheet_June2022_rev.pdf The CAR T-cell Therapy Process - https://www.lls.org/sites/default/files/2024-03/PS100_CART-CellTherapyProcessFlyer_0224.pdf Patient-Caregiver CAR T-cell Therapy Facts - https://www.lls.org/sites/default/files/2024-04/FS27_CART_Fact_Sheet_0424_rev.pdf Learn About CAR T-cell Therapy - https://www.lls.org/sites/default/files/2024-03/PS126_CART_ResourceCard_3_24.pdf Mantle Cell Lymphoma Facts for Patients and Caregivers -The Leukemia & Lymphoma Society https://lls.org/sites/default/files/2023-08/FS4_Mantle_Cell_Facts_0423rev.pdf